Bio Path Holdings Inc (BPTH)
$0.98
+0.01
(+1.33%)▲
Performance
- $0.93$0.98$0.98
5.1%
Downside
Day's Volatility :5.48%
Upside
0.4%
- $0.32$13.80$0.98
67.35%
Downside
52 Weeks Volatility :97.68%
Upside
92.9%
Returns
| Period | Bio Path Holdings Inc | Index (Russel 2000) |
|---|---|---|
3 Months | -60.33% | 0.0% |
6 Months | -84.21% | 0.0% |
1 Year | 152.35% | 0.0% |
3 Years | -82.14% | -22.3% |
Highlights
Market Capitalization | 2.5M |
Book Value | $0.56 |
Earnings Per Share (EPS) | -14.19 |
PEG Ratio | 0.0 |
Wall Street Target Price | 20.0 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -140.03% |
Return On Equity TTM | -366.18% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -13.0M |
Diluted Eps TTM | -14.19 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -6.2 |
EPS Estimate Next Year | -4.04 |
EPS Estimate Current Quarter | -1.54 |
EPS Estimate Next Quarter | -0.93 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 1940.82%
Technicals Summary
Sell
Neutral
Buy
Bio Path Holdings Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Bio Path Holdings Inc | -32.14% | -84.21% | 152.35% | -82.14% | -91.22% |
 Regeneron Pharmaceuticals, Inc. | 5.97% | 16.25% | 37.11% | 69.18% | 305.56% |
 Novo Nordisk A/s | 9.99% | -3.52% | 34.24% | 158.74% | 417.73% |
 Alnylam Pharmaceuticals, Inc. | -5.15% | 64.67% | 22.72% | 31.08% | 198.44% |
 Vertex Pharmaceuticals Incorporated | 0.45% | 14.0% | 36.06% | 143.5% | 167.72% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Bio Path Holdings Inc | NA | NA | 0.0 | -6.2 | -3.66 | -1.4 | NA | 0.56 |
Regeneron Pharmaceuticals, Inc. | 29.93 | 29.93 | 1.54 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 44.01 | 44.01 | 1.98 | 3.44 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.55 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.57 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Bio Path Holdings Inc | Buy | $2.5M | -91.22% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $124.7B | 305.56% | 29.93 | 32.04% |
Novo Nordisk A/s | Buy | $585.3B | 417.73% | 44.01 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $32.3B | 198.44% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $120.9B | 167.72% | 32.84 | -4.74% |
Insights on Bio Path Holdings Inc
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 69.2% return, outperforming this stock by 151.3%
Institutional Holdings
Armistice Capital, LLC
3.80%Vanguard Group Inc
0.53%BlackRock Inc
0.09%Tower Research Capital LLC
0.08%UBS Group AG
0.05%
Company Information
bio-path is a publicly traded biotechnology company focused on developing therapeutic products utilizing its proprietary dnabilize™ technology designed to distribute nucleic acid drugs throughout the human body with a simple intravenous infusion. the company’s initial focus is in oncology. bio-path’s lead product candidate, prexigebersen, (bp1001), is in phase ii clinical trials for aml in combination with ldac in elderly de novo patients. the safety segment of the phase ii trial for prexigebersen + dasatinib in blast-phase and accelerated phase cml patients is expected to begin in 2017. bio-path’s second drug candidate, bp1002, is ready for the clinic where it will be evaluated in lymphoma and solid tumors. the technology behind prexigebersen is called dnabilize™ technology. dnabilize is a liposomal antisense dna platform with two critical improvements in oligonucleotide therapeutics. the main benefits to the patient are, 1: we have never had a single patient experience thrombocytopen
Organization | Bio Path Holdings Inc |
Employees | 10 |
CEO | Mr. Peter H. Nielsen MBA |
Industry | Health Technology |
Discover More
A Spac I Acquisition Corp
$0.98
+1.33%
Keyarch Acquisition Corp
$0.98
+1.33%
Connexa Sports Technologies Inc
$0.98
+1.33%
Us Value Etf
$0.98
+1.33%
First Wave Biopharma Inc
$0.98
+1.33%
Global X Msci Next Emerging
$0.98
+1.33%
Fat Projects Acquisition Corp
$0.98
+1.33%
Capital Link Global Fintech
$0.98
+1.33%
Applied Uv Inc
$0.98
+1.33%